← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-7 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
ADCBiologicstaleAstraZenecaalonePhase 2

saruparib (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib))

Breast Cancer; Biliary Tract Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 13상태 RECRUITING
ADCBiologicstaleAstraZenecaalonePhase 2

AZD8205 and AZD5305 (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), saruparib)

Breast Cancer; Biliary Tract Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 13상태 RECRUITING
CGTBiologicstaleShanghai First Song Biotechnolo…Phase 1

Anti-CD30 CAR T cells (Anti-CD30 CAR T cells)

Adult T-Cell Lymphoma/Leukaemia; Anaplastic Large Cell Lymphoma · CD30

#CD30#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 13상태 ACTIVE
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 1

Anti-CEA-CAR T (Anti-CEA-CAR T)

Lung Cancer; Colorectal Cancer · CEA

#CEA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 13상태 ACTIVE
CGTBiologicstaleStephan Grupp MD PhDPhase 2

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 13상태 RECRUITING
ADCBiologicstaleCelldex TherapeuticsPhase 2

CDX-011 (CDX-011)

Breast Cancer · Metastatic gpNMB Over-expressing Triple

#MetastaticgpNMBOver-expressingTr#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 21%임상시험 13상태 ACTIVE
ADCBiologicstaleBayerPhase 2

Copanlisib Hydrochloride (Copanlisib Hydrochloride)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 38.5%임상시험 13상태 RECRUITING
AntibodystaleAmgenPreclinical

Dasatinib and blinatumomab (Dasatinib and blinatumomab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Preclinical#항체#면역항체+2
효능 ORR 10%임상시험 13상태 ACTIVE
ADCBiologicstaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Uterine Cervical Neoplasms · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+1
임상시험 13상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 3

Divarasib (Divarasib)

Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer · Solid Tumors

#SolidTumors#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING
CGTAAVBiologicstaleByron LamPhase 2

10e11 vg (Injection of AAV2-REP1, Injection of AAV2-REP1 (10e11 vg))

Choroideremia · Choroideremia

#Choroideremia#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 82.3%임상시험 13상태 ACTIVE
AntibodystaleBristol-Myers SquibbPhase 2

Lirilumab (Lirilumab)

Non-Hodgkin's Lymphoma; Hodgkin Lymphoma · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.7%임상시험 13상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

MK-5684 (MK-5684)

Castration-Resistant Prostatic Cancer; Metastasis · Castration-Resistant Prostatic Cancer

#Castration-ResistantProstaticCan#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 13상태 RECRUITING
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC and JS001)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 13상태 ACTIVE
AntibodystaleStemcentrxPhase 1

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

Small Cell Lung Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase1#항체#면역항체+3
효능 ORR 27.6%임상시험 13상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 2

Selicrelumab (Selicrelumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 37.5%임상시험 13상태 RECRUITING
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 42.9%임상시험 13상태 ACTIVE
ADCBiologicstaleAbbVieadizutecanPhase 2

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Metastatic Colorectal Cancer · Non Small Cell Lung Carcinoma

#NonSmallCellLungCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING
ADCBiologicstaleGenmabPhase 2

HuMax-TF-ADC (Tisotumab vedotin, Tisotumab vedotin (HuMax-TF-ADC))

Ovary Cancer; Cervix Cancer · Ovary Cancer

#OvaryCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 23.8%임상시험 13상태 ACTIVE
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Z-endoxifen (Z-endoxifen)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING

41 / 177 페이지

← 이전다음 →